Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FATE-NK100 and IL-2 for Refractory/Relapsed AML
NCT03081780Phase 1Completed
- Sponsor
- Masonic Cancer Center
- Start
- Apr 2017
- Primary completion
- Aug 2020
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of FATE-NK100 in acute myeloid leukemia (AML), sponsored by Masonic Cancer Center. Primary endpoint: Maximum Tolerated Dose at 3 months. Started Apr 2017; status: completed.
02
Drugs
FATE-NK100
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03081780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081780.